Physician profile
Ashley Conway
NPI 1750794525
$965.20
in general payments reported to CMS, 2019-2025
20 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.55 · 2021: $58.02 · 2022: $84.04 · 2023: $297 · 2024: $182 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $804.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $147.33 | 2025 | Wegovy |
| Pacira Pharmaceuticals Incorporated | $123.44 | 2023 | Exparel |
| Astellas Pharma US INC | $87.34 | 2023-2024 | Veozah |
| Pfizer INC. | $80.61 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $77.33 | 2022-2023 | |
| Organon LLC | $76.65 | 2021-2025 | Nexplanon, Jada System |
| Sumitomo Pharma America, INC. | $50.46 | 2024-2025 | Myfembree |
| Amgen INC. | $33.89 | 2022-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $32.70 | 2021-2023 | |
| Therapeuticsmd, INC. | $31.40 | 2020-2022 | |
| Boston Scientific Corporation | $28.45 | 2021 | |
| Shield Therapeutics INC | $27.84 | 2024-2025 | |
| Biogen, INC. | $27.34 | 2025 | Zurzuvae |
| Abbvie INC. | $24.19 | 2023 | Lo Loestrin Fe |
| Exeltis, USA INC. | $22.67 | 2023 | Slynd |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $20.33 | 2024 | Paragard T 380a |
| Dexcom, INC. | $19.46 | 2025 | Dexcom G6 Transmitter |
| Mylan Pharmaceuticals INC. | $19.24 | 2022 | |
| Daiichi Sankyo INC. | $18.45 | 2022 | |
| Millicent US INC | $16.08 | 2025 | Intrarosa, Femlyv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Conway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.